Liver Cancer

References & Evidence Notes

Each numbered entry below is either a source you can follow or a note setting out what the evidence does and does not support. Both are numbered together so the markers in the text line up.

Last reviewed October 20, 2026. Supplement entries are cross-checked against the NIH National Center for Complementary and Integrative Health and the Linus Pauling Institute Micronutrient Information Center.²⁸ Nothing on this page treats liver cancer. The nutrition here supports liver function and general nutritional status around treatment; it is not an alternative to resection, ablation, transplant, embolization or systemic therapy, and no dietary change should delay treatment decided with your hepatology and oncology team. And this page carries a risk the others do not: the liver is the organ that metabolizes what you swallow, so many herbs and supplements are hepatotoxic, including several sold specifically for liver health. In established liver disease the margin for error is small. Clear every single supplement with your hepatologist before taking it, including anything on this page. The highest-value interventions for liver cancer are not supplements at all: treating hepatitis C, suppressing hepatitis B, stopping alcohol and surveillance every six months if you have cirrhosis. Several supplements interact with cancer treatment.

1. On prevention, surveillance and surgery: 2023 practice guidance states that people with cirrhosis from any cause typically have about a 2% yearly risk of hepatocellular carcinoma, and that cirrhosis is present in over 80% of people with it. It recommends surveillance with ultrasound and AFP about every 6 months for adults with cirrhosis and for higher-risk groups with chronic hepatitis B, as a strong recommendation; hepatitis B vaccination for all newborns and unvaccinated high-risk adults; and antiviral treatment, since suppressing hepatitis B and clearing hepatitis C lower the risk. People with hepatitis C cirrhosis stay at raised risk for up to 10 years after the infection is cleared, so surveillance continues. Drinking alcohol alongside another liver disease can raise the risk as much as fivefold, fatty liver disease is the fastest-growing cause in transplant candidates, and people with chronic liver disease are advised to keep a healthy weight, eat a balanced diet and avoid tobacco and alcohol. Cohort meta-analyses link surveillance to earlier detection, more curative treatment and longer survival, and ablation is a curative option for a single tumor when surgery is not. In well-selected patients, resection gives 5-⁠year survival above 70%, PubMed 37199193. ↩
2. SEER (National Cancer Institute) liver and intrahepatic bile duct cancer statistics, and GLOBOCAN/IARC for global figures. seer.cancer.gov. Source for the estimate of 42,340 new US cases in 2026 and for the histology split, with hepatocellular carcinoma accounting for roughly 80 to 90% of primary liver cancer and cholangiocarcinoma most of the remainder. ↩
3. Milan criteria for liver transplantation in HCC (single tumor up to 5 cm, or up to three tumors each up to 3 cm, without vascular invasion or extrahepatic spread), first reported in a 1996 study of 48 people with cirrhosis and small tumors, 75% of whom were alive four years after transplant, PubMed 8594428. Transplant treats the cancer and the underlying cirrhosis together, which is why it is described as the reference standard for early HCC with cirrhosis. ↩
4. On intermediate-stage treatment: the 2022 update of the Barcelona Clinic Liver Cancer strategy names chemoembolization (TACE) as the treatment for suitable intermediate-stage patients and systemic therapy for those who are not candidates; it treats radioembolization (TARE) as equally effective in early-stage disease, but says no evidence-based recommendation can be made for it in advanced disease until positive trials are available. It gives the expected median survival as more than 5 years for very early and early stages, more than 2.5 years for intermediate, more than 2 years for advanced and 3 months for terminal disease, PubMed 34801630. ↩
5. Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3(12):1683-⁠1691. PubMed 28983565. Of 810,000 liver cancer deaths worldwide in 2015, hepatitis B accounted for 33%, alcohol for 30% and hepatitis C for 21%, with 16% from other causes. ↩
6. On hepatitis C: WHO states that direct-acting antiviral medicines clear the infection in more than 95% of people treated, usually within 12 to 24 weeks, and that there is no vaccine, WHO, hepatitis C. ↩
7. On tumor rupture: a 2022 review describes rupture of a liver cancer as a rare and life-threatening event that often needs urgent treatment, with abdominal pain its most common symptom, PubMed 35252016. ↩
8. On risk factors: the US National Cancer Institute lists chronic hepatitis B, the leading cause in Asia and Africa; chronic hepatitis C, the leading cause in North America, Europe and Japan; cirrhosis; heavy alcohol use; aflatoxin B1, a poison from a fungus that grows on corn and nuts stored in hot, humid places; NASH; cigarette smoking, with risk rising with the amount and years smoked; and rare conditions such as untreated hereditary hemochromatosis. It notes that replacing foods high in aflatoxin B1 can reduce the risk, NCI, liver cancer causes and prevention. ↩
9. On hepatitis B: WHO states that it can be prevented by vaccines that are safe, available and effective, that treatment with oral medicines can slow cirrhosis, reduce cases of liver cancer and improve long-term survival, and that most people who start treatment must continue it for life, WHO, hepatitis B. ↩
10. On surveillance: AASLD guidance recommends ultrasound with or without alpha-fetoprotein every six months for adults with cirrhosis, and AFP above 20 ng/mL warrants further evaluation. aasld.org. Surveillance is the reason early, curable HCC is found at all, and cohort meta-analyses link it to earlier detection, more curative treatment and longer survival. ↩
11. On hepatotoxicity of supplements: LiverTox, NCBI Bookshelf. Herbal and dietary supplements are a leading identified cause of drug-induced liver injury in US registries, and the products implicated include some marketed for liver support. This is the reason for the warning at the top of the supplement section. ↩
12. On coffee: Bravi F, et al. Coffee reduces risk for hepatocellular carcinoma, an updated meta-analysis. Clin Gastroenterol Hepatol. 2013, cghjournal.org, 16 studies and 3,153 cases, roughly 40% lower HCC risk for any coffee consumption against none; and later meta-analyses reporting about 35 to 43% lower risk per additional two cups a day, PubMed 32830818. These are observational, general-population figures. They are not specific to people who already have cirrhosis, and people who drink coffee differ from those who do not in ways cohorts cannot fully adjust for. Coffee is worth having; it is not a treatment. ↩
13. On acetaminophen in chronic liver disease: the commonly advised ceiling is 2 g/day rather than the usual 4 g, and it should be set with the treating team. Acetaminophen is not contraindicated in liver disease and is generally preferred to NSAIDs: a review of analgesics in chronic liver disease calls it the safest option at standard doses and advises avoiding NSAIDs, which carry bleeding and renal risks in cirrhosis and hepatotoxic potential of their own, PubMed 40904659. ↩
14. IMbrave150: Finn RS, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894-⁠1905. Source for atezolizumab plus bevacizumab as first-line therapy, having shown superior overall and progression-free survival against sorafenib. That comparison is between two drug regimens, not between a supplement and a drug. ↩
15. On systemic therapy for advanced liver cancer: current oncology guidance says atezolizumab plus bevacizumab or durvalumab plus tremelimumab may be offered first line to people with Child-Pugh A liver function and good performance status, and sorafenib, lenvatinib or durvalumab where those combinations are contraindicated, PubMed 38502889. ↩
16. On muscle loss in cirrhosis: a meta-analysis of 39 studies with 12,827 patients found sarcopenia on CT in 44% of people with cirrhosis, and found it an independent predictor of death, with about twice the risk, PubMed 39035068. ↩
17. On antioxidant supplements during cancer treatment: the US National Cancer Institute notes that randomized trials have had mixed results, that some found worse outcomes in people who took antioxidant supplements during cancer therapy, especially smokers, and that people with cancer should tell their doctors about any dietary supplement they use, NCI, antioxidants and cancer prevention. ↩
18. Gencer B, Djousse L, Al-Ramady OT, Cook NR, Manson JE, Albert CM. Effect of long-term marine omega-⁠3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis. Circulation. 2021;144(25):1981-⁠1990. PubMed 34612056. Seven trials with 81,210 people followed for about 5 years: omega-⁠3 supplements were linked to a higher risk of atrial fibrillation (hazard ratio 1.25), more so in trials of more than 1 g a day (1.49), and the risk rose with each additional gram. ↩
19. On branched-chain amino acids around liver cancer treatment: a meta-analysis of 11 randomized trials with 750 patients having resection, embolization or ablation found no difference in tumor recurrence or overall survival, but higher serum albumin, fewer cases of ascites and higher body weight with supplementation, PubMed 37642137. ↩
20. On milk thistle: in a double-blind randomized trial of 200 people with alcohol-related cirrhosis, silymarin 450 mg a day had no effect on survival or the course of the disease, PubMed 9566830. NIH reviewers describe trial results across liver diseases as conflicting or too limited to draw conclusions, and advise anyone taking medicine to talk with their clinician first because some herbs and medicines interact, NCCIH, milk thistle. ↩
21. On selenium and cancer: a Cochrane review found that in randomized trials at low risk of bias, selenium supplements did not change the incidence of any cancer (risk ratio 1.01) and slightly raised the risk of type 2 diabetes, PubMed 29376219. ↩
22. On selenium: the adult tolerable upper intake level is 400 mcg/day, which is the basis for the ceiling given on this page. ↩
23. On vitamin K: the adequate intake is 90 mcg/day for women and 120 mcg/day for men, and in people on vitamin K antagonist anticoagulants, daily MK-⁠7 doses as low as 10 to 20 mcg may undermine anticoagulant stability, Linus Pauling Institute. In a double-blind trial of 548 people after curative treatment of liver cancer, vitamin K2 at 45 or 90 mg/day, a different form (MK-⁠4), did not prevent recurrence or death, PubMed 21574174. ↩
24. On treatment: NHS guidance says treatment depends on the size and type of the cancer, where it is, whether it has spread and general health. Small, early cancers may be removed by surgery or a transplant, or destroyed with heat; chemoembolization, internal radiation therapy, targeted medicines and immunotherapy are used when surgery is not possible. Checkups continue during and after treatment, and where the cancer cannot be removed, treatment aims to limit it and its symptoms and help people live longer, with a palliative care team, NHS, liver cancer treatment. ↩
25. On sudden abdominal pain: NHS guidance says to call emergency services or go to an emergency department if a stomach ache comes on very suddenly or is severe, NHS, stomach ache. ↩
26. On emergencies with liver disease: NHS guidance advises people with cirrhosis to call emergency services if they vomit blood, pass very dark or black stools, or suddenly become confused or develop slurred speech, and to get an urgent appointment for yellowing of the skin or eyes, a swollen abdomen, legs or ankles, or more breathlessness than usual, NHS, cirrhosis. ↩
27. On fever during treatment: NHS guidance says to call your care team right away for a high temperature, feeling hot, cold, sweaty or shivery, or other signs of infection. The US National Cancer Institute lists a fever of 100.5°F (38°C) or higher as a sign of infection and says infections during cancer treatment can be life-threatening and need urgent medical attention, NHS, chemotherapy side effects, NCI, infection during cancer treatment. ↩
28. National Center for Complementary and Integrative Health (NIH), nccih.nih.gov, and the Linus Pauling Institute Micronutrient Information Center, lpi.oregonstate.edu/mic. ↩